Key Points - Tianpu Co., Ltd. announced a suspension of trading for stock verification due to multiple instances of abnormal trading fluctuations from August 22 to September 3, with a reminder for investors about market risks [1] - China Shipbuilding Industry Corporation announced a share exchange ratio of 1:0.1339 for the merger with China Shipbuilding, with the stock ceasing to be listed from September 5, 2025 [2] - Chengdu Huamei reported that its 40G high-precision RF ADC chip is still in the trial production stage and has not achieved mass sales, indicating market demand uncertainty [2] - Taihe Technology's sulfide solid electrolyte project is currently in the trial production phase and has not generated sales revenue [3] - Robotech signed a contract worth approximately €946.50 million for fully automated silicon photonic packaging equipment, expected to positively impact the company's future performance [4] - Wento Holdings reported that its cinema and gaming businesses are still in the recovery phase post-restructuring, with potential uncertainties in future operations [5] - Xibu Muye's fresh milk production increased by 4.8% month-on-month in August [6] - China Shipbuilding announced the implementation of a share exchange merger with China Heavy Industry [6] - Gansu Energy plans to invest CNY 40.89 billion in a wind-solar integrated project [6] - Xinhua Medical's endoscope cleaning workstation received a Class II medical device registration certificate [6]

证券日报网讯 9月3日晚间，康恩贝发布公告称，近日，公司收到国家药品监督管理局核准签发的苓桂 术甘汤颗粒《药品注册证书》。 （文章来源：证券日报） ...

北京商报讯(记者王寅浩实习记者宋雨盈)9月3日，康恩贝（600572）发布公告称，公司近日收到国家药 品监督管理局核准签发的苓桂术甘汤颗粒《药品注册证书》。公告显示，苓桂术甘汤颗粒具有温阳化 饮、健脾利湿功效，主治中阳不足之痰饮。 ...

Group 1 - Shengtun Mining plans to repurchase shares worth between 500 million and 600 million yuan, with a maximum repurchase price of 11.82 yuan per share, aimed at employee stock ownership plans or equity incentives [1] - Kangnbei received a drug registration certificate for Linggui Shugan Granules, which is derived from traditional Chinese medicine and is used for treating phlegm and dampness due to Yang deficiency [2] - Zhangjiang Hi-Tech intends to publicly transfer 100% equity and related debts of Shanghai Jixin Rui Construction Technology Co., Ltd. with a total price not less than 151 million yuan [3] Group 2 - Shankai Intelligent won a bid for a metering device procurement project worth 13.318 million yuan from Hohhot Water Supply Company [4] - Hason Co. plans to jointly establish a supply chain company with a registered capital of 10 million yuan, in which Hason will hold a 10% stake [5] - Pudong Construction's subsidiaries won multiple major projects with a total amount of 1.271 billion yuan [6] Group 3 - Jinling Pharmaceutical received approval for the Phase III clinical trial of Olaratogrel tablets, which are used for treating moderate to severe pain associated with endometriosis [8] - Menohua's subsidiary obtained a drug registration certificate for Mosapride Citrate Tablets, aimed at improving gastrointestinal symptoms [10] - Shapuaisi's major shareholder plans to reduce holdings by up to 2% of the company's shares due to personal financial needs [11] Group 4 - Changyuan Power reported an August electricity generation of 3.771 billion kWh, a year-on-year decrease of 6.03% [15][16] - Xibu Livestock's August fresh milk production increased by 4.8% month-on-month but decreased by 7.27% year-on-year [19] - Yong'an Pharmaceutical's actual controller and chairman had their detention lifted, allowing them to resume normal duties [20] Group 5 - Jinkai Intelligent's director resigned due to work adjustments [22] - Xinhua Medical received a Class II medical device registration for an endoscope cleaning workstation [23] - Haishi Science and Technology's innovative drug HSK47388 received approval for a new indication clinical trial [25] Group 6 - Baotai Co. plans to participate in a land use rights auction in Baoji City with a starting price of 57.34 million yuan [26] - Minfeng Special Paper received a government subsidy totaling 11.2 million yuan [27] - Jiuchang Bio obtained a medical device registration for a heparin-binding protein assay kit [29] Group 7 - Jingao Technology plans to repurchase shares worth between 200 million and 400 million yuan, with a maximum price of 17.36 yuan per share [31] - Youxunda won a bid for a metering equipment project from China Southern Power Grid worth approximately 161 million yuan [32] - Qianli Technology reported an August vehicle sales increase of 168.55% year-on-year [32] Group 8 - Guangzhou Port expects an August container throughput increase of 1.2% year-on-year [32] - Kexing Pharmaceutical's GB08 injection completed the first subject enrollment for Phase II clinical trials [33] - Wu Ming Pharmaceutical plans to transfer 98.9% of its subsidiary's shares to a newly established wholly-owned subsidiary [34] Group 9 - Shanghai Electric's acquisition of K-Electric Limited shares has not yet completed the transfer [35] - Fulai New Materials plans to raise no more than 710 million yuan through a private placement [36] - Huaren Health's drug registration application for a new type of potassium ion competitive acid blocker has been accepted [37]

Group 1 - The core point of the article is that Zhejiang Kangnbei Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of Linggui Zhugan Decoction Granules, which is expected to positively impact the company's performance [1][2]. - The drug is classified as a traditional Chinese medicine (Category 3.1) and is intended for the treatment of symptoms related to insufficient middle yang and phlegm-dampness [1][2]. - The company has invested approximately 12.7 million RMB in the research and development of this drug [2]. Group 2 - As of the announcement date, there are four approved drug registration numbers for Linggui Zhugan Decoction Granules, with the company being the fourth to receive approval [2]. - The market for cardiovascular disease medications, including traditional Chinese medicine, reached a total sales amount of 50.431 billion RMB in 2024, showing a year-on-year decline of 3.10% [2]. - The sales amount for Linggui Zhugan Decoction Granules in 2024 was reported to be 210,000 RMB, following its market entry in December 2022 [2].

人民财讯9月3日电，康恩贝（600572）9月3日晚间公告，公司近日收到国家药监局核准签发的苓桂术甘 汤颗粒《药品注册证书》。苓桂术甘汤颗粒来源于汉代张仲景《金匮要略》，具有温阳化饮、健脾利湿 功效，主治中阳不足之痰饮。 ...

Core Viewpoint - The company Kangnibei (600572.SH) has received approval from the National Medical Products Administration for the registration certificate of Linggui Zhugan Decoction Granules, indicating a significant advancement in its product offerings [1] Group 1: Product Information - Linggui Zhugan Decoction Granules are derived from Zhang Zhongjing's "Jinkui Yaolue" from the Han Dynasty, known for its warming, diuretic, and spleen-strengthening effects [1] - The decoction is indicated for conditions related to insufficient middle yang and phlegm retention, with symptoms including fullness in the chest and flanks, dizziness, palpitations, shortness of breath, cough, white and slippery tongue coating, and wiry and slippery pulse [1] - The formula consists of four key ingredients: Poria, Cinnamon Twig, Atractylodes, and Licorice [1]